News | Heart Valve Technology | May 23, 2016

Mitralign Raises $40M in Equity Financing

Funding will be used to pursue U.S. and European regulatory approval of Trialign system, European launch of Mitralign Percutaneous Annuloplasty System

Mitralign, Series E funding, Trialign, MPAS

May 23, 2016 — Mitralign Inc. announced it has raised $39.8 million to date in a Series E equity round of financing. With the Series E financing raised, the company plans to continue growing its platform by pursuing U.S. and CE regulatory approval for the commercialization of their Trialign system in parallel with preparations for commercial launch in Europe of their Mitralign Percutaneous Annuloplasty System (MPAS). This includes completion of the SCOUT early feasibility study in the United States and the initiation of the SCOUT II Study to support the CE Mark in Europe.  

Both the Trialign and MPAS Systems feature a customizable therapy solution in concert with an extremely small footprint, which leaves all clinical options open for the physician, a key consideration for a front-line intervention.  The Trialign System is currently enrolling patients in an early feasibility investigational device exemption (IDE) study in the United States and is not approved for sale or distribution. The MPAS received CE mark approval in February for the treatment of functional mitral regurgitation (FMR).

For more information: www.mitralign.com

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
Overlay Init